The ADORE trial (adjuvant oxaliplatin in rectal cancer) is a multicenter, randomized trial in patients with postoperative ypStage II (ypT3-4N0) or III (ypT<sub>any</sub>N1-2) rectal cancer after fluoropyrimidine-based preoperative CRT and TME.
At present, the clinical guidelines recommend ACT for patients with stage II/III (ypT3-4 N0 or ypTanyN1-2) rectal cancer following neoadjuvant CRT and surgery.
DMI was not a significant predictive factor for recurrence in patients with ypT3rectal cancer who underwent preoperative CRT, and ypN+ was the only independent predictive factor for recurrence.